Prospective of curcumin, a pleiotropic signalling molecule from Curcuma longa in the treatment of Glioblastoma

Luthra, Pratibha Mehta; Lal, Neetika

doi:10.1016/j.ejmech.2015.11.049

Cited by 62 publications

(51 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fibrosarcoma cells it prevents the Erk phosphorylation and activity of MMP-2 & 9. And, in gastric carcinoma cells it suppresses the Erk, JNK, and MMP-9 expressions (Luthra and Lal, 2016). …”

Section: Molecular Targets and Mechanisms Of Action Of Anticancer Phymentioning

confidence: 99%

Lead Phytochemicals for Anticancer Drug Development

et al. 2016

View full text Add to dashboard Cite

Cancer is a serious concern at present. A large number of patients die each year due to cancer illnesses in spite of several interventions available. Development of an effective and side effects lacking anticancer therapy is the trending research direction in healthcare pharmacy. Chemical entities present in plants proved to be very potential in this regard. Bioactive phytochemicals are preferential as they pretend differentially on cancer cells only, without altering normal cells. Carcinogenesis is a complex process and includes multiple signaling events. Phytochemicals are pleiotropic in their function and target these events in multiple manners; hence they are most suitable candidate for anticancer drug development. Efforts are in progress to develop lead candidates from phytochemicals those can block or retard the growth of cancer without any side effect. Several phytochemicals manifest anticancer function in vitro and in vivo. This article deals with these lead phytomolecules with their action mechanisms on nuclear and cellular factors involved in carcinogenesis. Additionally, druggability parameters and clinical development of anticancer phytomolecules have also been discussed.

show abstract

Section: Molecular Targets and Mechanisms Of Action Of Anticancer Phymentioning

confidence: 99%

Lead Phytochemicals for Anticancer Drug Development

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For medullary impact in another therapeutic Institute had seen fit to suspend it for palliative therapy. The haematochemical and general condition improvement after strong supportive therapy lead to set a new specific treatment with bevacizumab [4,5] (tri-weekly basis and at a dose of 10 mg/kg), capacitive hyperthermia every other day (55 minutes each therapeutic session) [6][7][8], curcumin (100 mg four times daily) [9,10], Boswellia serrata (400 mg four times daily) [11].…”

Section: Case Reportmentioning

confidence: 99%

Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy

Pastore¹,

Fioranelli²,

Roccia³

2017

J Integr Oncol

View full text Add to dashboard Cite

Glioblastoma multiforme is a pathology that is poorly treatable and tends towards recurrence. If surgically unresectable, at least without macroscopically visible residue, the prognosis is severe. Here is the case of a 60-yearold woman suffering from recurrent glioblastoma who comes to my observation with no therapeutic options and treated with a combination of antiangiogenic drug, RF capacitive hyperthermia and herbal medicine, earns an acceptable quality of life and survival prolongation of six months.

show abstract

“…It modulates cell proliferation and apoptosis via a number of signaling pathways, and detailed action of cucurmin was recently reviewed 30. Of note, cucurmin crossed the blood–brain barrier31 and reduced the tumor size 32–34.…”

Section: Introductionmentioning

confidence: 99%

Strategies of temozolomide in future glioblastoma treatment

Lee¹

2017

OTT

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) may be one of the most challenging brain tumors to treat, as patients generally do not live more than 2 years. This review aimed to give a timely review of potential future treatments for GBM by looking at the latest strategies, involving mainly the use of temozolomide (TMZ). Although these studies were carried out either in vitro or in rodents, the findings collectively suggested that we are moving toward developing a more efficacious therapy for GBM patients. Nanoparticles preparation was, by far, the most extensively studied strategy for targeted brain delivery. Therefore, the first section of this review presents a treatment strategy using TMZ-loaded nanocarriers, which encompassed nanoparticles, nanoliposomes, and nanosponges. Besides nanocarriers, new complexes that were formed between TMZ and another chemical agent or molecule have shown increased cytotoxicity and antitumor activity. Another approach was by reducing GBM cell resistance to TMZ, and this was achieved either through the suppression of metabolic change occurring in the cells, inhibition of the DNA repair protein, or up-regulation of the protein that mediates autophagy. Finally, the review collates a list of substances that have demonstrated the ability to suppress tumor cell growth.

show abstract

Prospective of curcumin, a pleiotropic signalling molecule from Curcuma longa in the treatment of Glioblastoma

Cited by 62 publications

References 114 publications

Lead Phytochemicals for Anticancer Drug Development

Lead Phytochemicals for Anticancer Drug Development

Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy

Strategies of temozolomide in future glioblastoma treatment

Contact Info

Product

Resources

About